Your browser doesn't support javascript.
loading
Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
Zhang, Qingbin; Qian, Mengxin; Wu, Yong; Wang, Yapeng; Shangguan, Wenwen; Lu, Jianguang; Zhao, Wenjie; Feng, Jun.
Afiliação
  • Zhang Q; State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
  • Qian M; School of Pharmacy, Fudan University, Shanghai, 201203, China.
  • Wu Y; State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China; Shanghai Duomirui Biotechnology Co., Ltd., Shanghai, 201203, China.
  • Wang Y; State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China.
  • Shangguan W; School of Pharmacy, Fudan University, Shanghai, 201203, China.
  • Lu J; State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China; Shanghai Duomirui Biotechnology Co., Ltd., Shanghai, 201203, China.
  • Zhao W; State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China; Shanghai Duomirui Biotechnology Co., Ltd., Shanghai, 201203, China.
  • Feng J; State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, China; Shanghai Duomirui Biotechnology Co., Ltd., Shanghai, 201203, China. Electronic address: fengjdmr@163.com.
Eur J Pharmacol ; 904: 174152, 2021 Aug 05.
Article em En | MEDLINE | ID: mdl-33964292

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Fragmentos Fab das Imunoglobulinas / Albuminas / Adalimumab / Anti-Inflamatórios Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Fragmentos Fab das Imunoglobulinas / Albuminas / Adalimumab / Anti-Inflamatórios Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article